| CELLECTAR BIOSCIENCES |
| USA |
| Gesundheit |
| US15117F8804 / A41BQ3 |
| NV40 (Frankfurt) / CLRB (NASDAQ) |
| FRA:NV40, ETR:NV40, NV40:GR, NASDAQ:CLRB |
| - |
| https://www.cellectar.com.. |
|
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative cancer treatments. The company leverages its proprietary Phospholipid Drug Conjugate (PDC) delivery..
>Volltext.. |
| 9.37 Mio. EUR |
| -0.06 Mio. EUR |
| - |
| -19.72 Mio. EUR |
| -18.88 Mio. EUR |
| -8.96 EUR |
| 0.35 Mio. EUR |
| 11.43 Mio. EUR |
| -20.03 Mio. EUR |
| 2.78 |
| - |
| 51.12% |
| - |
| - |
| - |
| - |
| CELLECTAR |
| 05.04.26 |
|